Publication

Article

CURE

Fall 2007
Volume6
Issue 5

Diagnosis Delay

Delayed diagnosis too common.

Experts stress the importance of catching cancer early at its most treatable stage. But in the childhood population, cancer is usually so rare that it’s often overlooked when a child initially has symptoms. The delay in diagnosis can be costly since most childhood cancers are considered fast-growing.

Researchers examined 23 studies conducted between 1976 and 2006 to find any underlying patterns that may contribute to delayed diagnosis, which included the time it took parents to take the child to a physician after symptoms appeared, and from the first health care visit to cancer diagnosis.

Findings of the study, published in August in the journal Cancer, found physician delays to be longer than parent delays in the majority of studies. Factors influencing time to diagnosis included the child’s age, parents’ education level, symptoms, cancer stage, the initial medical specialty consulted, and most significantly, the type of cancer. How those factors relate to prognosis and outcome remains unknown.

The analysis, concluded the authors, is the first step in developing new strategies and programs to shor ten the delay in diagnosis for childhood cancer patients.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of man wearing baseball cap backwards.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
Image of doctor with brown hair.
Image of man with black hair.
Related Content